AIM Rule 17 and Schedule 2(g) Update

7 May 2025

Physiomics plc

("Physiomics" or the "Company")

Update re: AIM Rule 17 - Schedule Two (g) Director's Disclosure

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, provides the following update in accordance with AIM Rule 17 and Schedule Two(g) sub-paragraph (v) of the AIM Rules for Companies:

Dr. Timothy Corn, a Non-Executive Director of the Company, is an Executive Director of Oxford Cannabinoid Technologies Holdings plc ("OCT"), a public company incorporated in England and Wales, having been appointed to this role in November 2023. On 2 May 2025, OCT was placed into administration.

For more information about Physiomics and its services, please visit www.physiomics.co.uk.

Enquiries:

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.